Zoetis (NYSE:ZTS) Price Target Cut to $230.00

Zoetis (NYSE:ZTS) had its target price decreased by Barclays from $260.00 to $230.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 52.43% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the company. Stifel Nicolaus lowered their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Piper Sandler reissued an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group upped their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus price target of $218.00.

Zoetis Stock Performance

Shares of ZTS stock opened at $150.89 on Tuesday. The stock has a market cap of $69.01 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.85. The stock has a 50-day moving average of $173.11 and a 200-day moving average of $179.58. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. Zoetis has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 EPS. As a group, sell-side analysts expect that Zoetis will post 5.79 earnings per share for the current year.

Insider Activity

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 2,209 shares of company stock worth $371,293. 0.15% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Blue Bell Private Wealth Management LLC lifted its holdings in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Webster Bank N. A. lifted its stake in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Moisand Fitzgerald Tamayo LLC boosted its holdings in Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after acquiring an additional 96 shares during the last quarter. Independence Bank of Kentucky increased its position in Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Finally, Private Wealth Management Group LLC bought a new position in Zoetis during the 4th quarter worth approximately $33,000. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.